Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma

Completed · Phase 2

Conditions studied: Multiple Myeloma

In brief

This is a research study to see if a new drug called bortezomib is useful to treat multiple myeloma in people who are newly diagnosed, and have not yet received treatment for their disease. VELCADE® (bortezomib) for Injection is a drug under development by Millennium Pharmaceuticals, Inc.

Key facts

Study ID

NCT01090921

Run by

Boston VA Research Institute, Inc.

People needed

50

Starts

2007-05-01

Expected to finish

2015-03-01

Last updated by the study team

2020-09-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of multiple myeloma based on standard criteria.
• Measurable disease, defined as a monoclonal immunoglobulin spike on serum electrophoresis of > 1Gm/dL and/or urine monoclonal immunoglobulin spike of > 200mg/24 hours.
• Non-secretors must have measurable protein by Freelite or measurable disease such as plasmacytoma to be eligible.
• Patient must not have been previously treated with chemotherapy. Prior treatment of hypercalcemia with corticosteroids, or bisphosphonates does not disqualify the patient.
• Patient must be ineligible for autologous stem cell transplant due to one or more of the following reasons:
• Age>65
• Impaired renal function (creatinine≥2.0 mg/dL)
• Impaired pulmonary function (DLCO≤50%)
• Poor performance status (KPS≤80)
• Other prohibitive comorbid disorder
• 5b. Patients≥60 who decline autologous stem cell transplant are eligible for this study.
• 5c. Patients who are eligible but wish to postpone autologous stem cell transplant are eligible for this study.
• Karnofsky performance status>50
• Patients treated with local radiotherapy with or without a brief exposure to steroids are eligible. Patients who require concurrent radiotherapy should have entry to the protocol deferred until the radiotherapy is completed, followed by a four week wash out period Spot RT to ≤3 vertebrae acceptable prior to entry.
• Meets the following pretreatment laboratory criteria at Baseline (Within 14 days prior to study drug administration):
• Platelet count>50x10\^9/L or, if the bone marrow is extensively infiltrated,>30x10\^9/L
• Hemoglobin>8.0G/dL
• Absolute neutrophil count >1.0x10\^9/L or, if the bone marrow is extensively infiltrated, >0.5x10\^9/L
• Meets the following pretreatment laboratory criteria for liver function tests at the screening visit conducted within 14 days of registration
• AST (SGOT): <3 times the upper limit of institutional laboratory normal
• ALT (SGPT): <3 times the upper limit of institutional laboratory normal
• Total bilirubin: <2 times the upper limit of institutional laboratory normal, unless clearly related to the disease
• Women with child-bearing potential should be practicing an adequate form of contraception, as judged by the investigator (i.e. birth control pills, double barrier method, abstinence, etc.) or be surgically sterile or 12 months post-menopausal. Male subject agrees to use an acceptable method for contraception for the duration of the study.
• Age 18 years or older
• Has given voluntary written informed consent.

You may not qualify if…

• POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein (M-protein) and skin changes)
• Plasma cell leukemia
• Impaired kidney function requiring dialysis, patients on hemodialysis are excluded
• Receiving steroids >the equivalent of 10mg prednisone daily for other medical conditions, e.g., asthma, systemic lupus erythematosis, rheumatoid arthritis
• Infection not controlled by antibiotics
• HIV infection. Patients should provide consent for HIV testing according to the institution's standard practice
• Known active hepatitis B or C
• Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure (Appendix D), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
• Second malignancy requiring concurrent treatment
• Other serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol
• Positive pregnancy test in women of childbearing potential
• Patient has hypersensitivity to boron or mannitol.
• Patient has ≥Grade 2 peripheral neuropathy within 14 days before enrollment.
• Patient has received other investigational drugs with 14 days before enrollment

Where it is running

• Little Rock VA Medical Center — Little Rock, Arkansas, United States
• West Los Angeles VA Medical Center — Los Angeles, California, United States
• San Francisco VA Medical Center — San Francisco, California, United States
• Eastern Colorado Health Care System — Denver, Colorado, United States
• West Haven VA Medical Center — West Haven, Connecticut, United States
• Tampa VA Medical Center — Tampa, Florida, United States
• Atlanta VA Medical Center — Atlanta, Georgia, United States
• VA Boston Healthcare System — Jamaica Plain, Massachusetts, United States
• Kansas City VA Medical Center — Kansas City, Missouri, United States
• Pittsburgh VA Medical Center — Pittsburgh, Pennsylvania, United States
• Michael E. DeBakey VA Medical Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.